Block Listing Return

Diaceutics PLC

07 October 2024

 

Diaceutics PLC

BLOCK LISTING RETURN

Belfast and London, 7 October 2024 - Diaceutics PLC (AIM: DXRX), a leading technology and solutions provider to the pharma and biotech industry industry, gives the below information required by Schedule 6 of the AIM Rules for Companies in connection with the the UK and Global Share Incentive Plan for employees (the "SIP") and the Employee Share Option Plan (the "ESOP") which includes long term incentive awards.

Name of applicant:		Diaceutics PLC
Name of scheme:		UK and Global Share Incentive Plan for employees (the "SIP") and the Employee Share Option Plan (the "ESOP") which includes long term incentive awards.
Period of return:	From:	6 April 2024	To:	6 October 2024
Balance under scheme from previous return:		1,453,560 Ordinary Shares of £0.002 each
The amount by which the block scheme has been increased, if the scheme has been increased since the date of the last return:		N/A
Number of securities issued/allotted under schemes during period:		30,149 Ordinary Shares
Balance under scheme not yet issued/allotted at end of period		1,423,411  Ordinary Shares
Number and class of securities originally listed and the date of admission		1,500,000  Ordinary Shares on 6 October 2023
Total number of securities in issue at the end of the period		84,726,935 Ordinary Shares of £0.002 each
Name of contact:		Nick Roberts
Telephone number of contact:		As below

Enquiries:

Diaceutics PLC	Tel: [phone]
Nick Roberts, Chief Financial Officer	[e-mail]
Canaccord Genuity Limited (Nomad & Broker)	Tel: [phone]
Simon Bridges, Andrew Potts, Harry Rees
Alma Strategic Communications	Tel: [phone]
Caroline Forde, Kinvara Verdon	[e-mail]

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome.

We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network®.

 

END